Montreal, QC – Procyon Biopharma says it has received the 2005 Frost & Sullivan Award for Excellence in Technology in the field of emerging cancer therapies and that acknowledges Procyon’s overall scientific and technological contributions towards the advancement of cancer therapy.
The recognition comes through extensive market research and analysis conducted by Frost & Sullivan’s industry analysts, who have recently completed a study entitled “Cancer Therapies: Technology Assessment in North America” in which Procyon’s PCK3145 therapeutic program is featured. “Procyon’s PCK3145 meets all of the criteria we look for when selecting promising new emerging cancer therapies” said AN Aditya, research analyst with Frost & Sullivan. “We congratulate Procyon on their achievement.”
“I would like to take this opportunity also to acknowledge our scientific and clinical collaborators and their teams who have contributed significantly to both the elucidation of the receptor and several mechanism of action, and the progress of PCK3145 through the clinic,” says Hans J Mader, president and CEO of Procyon. “t appears from the recent ASCO meeting that drugs acting through multiple mechanisms will become the norm of future cancer treatments” he added.